Heron Therapeutics commences $150M common stock offering
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
Heron Therapeutics Inc. said it commenced an underwritten public offering of $150 million of shares of its common stock.
Heron will grant underwriters a 30-day option to purchase up to an additional 15% of the shares in the offering.
BofA Merrill Lynch, Cowen and Co. LLC and Leerink Partners LLC are acting as joint book-running managers for the offering.
